莫西沙星联合阿米卡星治疗耐多药肺结核的疗效研究(1)
 |
| 第1页 |
参见附件。
[摘要] 目的 探讨莫西沙星联合阿米卡星治疗耐多药肺结核的疗效。 方法 选择2008年1月～2010年1月我院收住的80例MDR—TB患者作为研究对象。所有患者在治疗中均全程加用常规保肝药物。观察组：6ADL2EM/18DL2EM(6个月A、D、L、E、M，18个月D、L、E、M)；对照组：6ADL2EV/18DL2EV(6个月A、D、L、E、V，18个月D、L、E、V)，比较两组的痰菌阴转率、疗效以及空洞闭合率、不良反应。 结果 两组随着治疗时间延长，其痰菌阴转率明显升高，且观察组痰菌阴转率升高较对照组显著，差异有统计学意义(P < 0.05)。观察组咳嗽、咯痰症状改善时间显著短于对照组，而观察组治疗后的有效率及空洞闭合率明显高于对照组，差异有统计学意义(P < 0.05)。 结论 莫西沙星联合阿米卡星治疗耐多药肺结核疗效确切，安全性好，值得推广和应用。
[关键词] 耐多药肺结核；莫西沙星；阿米卡星
[中图分类号] R521 [文献标识码] B [文章编号] 1673—9701(2012)24—0052—02
Efficacy of moxifloxacin combined with amikacin in treatment of multidrug—resistant tuberculosis
GAO Weihong LEI Tao
Lung Department， Beijiao Branch of the Second Hospital of Ningbo City， Ningbo 315010， China
[Abstract] Objective To investigate the efficacy of moxifloxacin combined with amikacin in treatment of multidrug—resistant tuberculosis. Methods From January 2008 to January 2010， 80 cases of MDR—TB patients were selected as research subjects. All patients in the treatment of the whole added to conventional hepatoprotective drug. Observation group： 6ADL2EM/18DL2EM (meaning 6 A and D， L， E， M， 18 D， L， E， M)； control group： 6ADL2EV/18DL2EV (meaning 6 A， D， L， E， V， 18 D， L， E， V). Results With the extension of treatment time， the sputum conversion rate was significantly increased， and the observation group sputum conversion rate increased more than the control group， the difference was statistically significant (P < 0.05). Cough， expectoration symptoms improved significantly shorter than the control group， while the observation group treatment efficiency and cavity closure rate were significantly higher， and the difference were statistically significant (P < 0 ......
您现在查看是摘要介绍页，详见PDF附件(1740kb)。